PL2579874T3 - Płynna kompozycja do wstrzykiwania zawierająca buprenorfinę - Google Patents

Płynna kompozycja do wstrzykiwania zawierająca buprenorfinę

Info

Publication number
PL2579874T3
PL2579874T3 PL11728037T PL11728037T PL2579874T3 PL 2579874 T3 PL2579874 T3 PL 2579874T3 PL 11728037 T PL11728037 T PL 11728037T PL 11728037 T PL11728037 T PL 11728037T PL 2579874 T3 PL2579874 T3 PL 2579874T3
Authority
PL
Poland
Prior art keywords
buprenorphine
flowable composition
injectable flowable
injectable
composition
Prior art date
Application number
PL11728037T
Other languages
English (en)
Inventor
Richard L. Norton
Andrew Watkins
Mingxing Zhou
Original Assignee
Indivior Uk Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42471306&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL2579874(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Indivior Uk Limited filed Critical Indivior Uk Limited
Publication of PL2579874T3 publication Critical patent/PL2579874T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Emergency Medicine (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Rheumatology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Materials For Medical Uses (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PL11728037T 2010-06-08 2011-06-06 Płynna kompozycja do wstrzykiwania zawierająca buprenorfinę PL2579874T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1009549.5A GB2481018B (en) 2010-06-08 2010-06-08 Injectable flowable composition comprising buprenorphine
PCT/GB2011/051057 WO2011154724A2 (en) 2010-06-08 2011-06-06 Compositions
EP11728037.0A EP2579874B1 (en) 2010-06-08 2011-06-06 Injectable flowable composition comprising buprenorphine

Publications (1)

Publication Number Publication Date
PL2579874T3 true PL2579874T3 (pl) 2018-05-30

Family

ID=42471306

Family Applications (1)

Application Number Title Priority Date Filing Date
PL11728037T PL2579874T3 (pl) 2010-06-08 2011-06-06 Płynna kompozycja do wstrzykiwania zawierająca buprenorfinę

Country Status (31)

Country Link
US (1) US8921387B2 (pl)
EP (3) EP2579874B1 (pl)
JP (2) JP5986072B2 (pl)
KR (1) KR101865689B1 (pl)
CN (1) CN103079544B (pl)
AU (1) AU2011263478B2 (pl)
BR (1) BR112012031290A2 (pl)
CA (1) CA2801676C (pl)
CL (1) CL2012003462A1 (pl)
CO (1) CO6670529A2 (pl)
CY (1) CY1120761T1 (pl)
DK (2) DK3360538T3 (pl)
ES (2) ES2656938T3 (pl)
FI (1) FI3360538T3 (pl)
GB (2) GB2481018B (pl)
HR (1) HRP20180118T1 (pl)
HU (1) HUE038275T2 (pl)
IL (2) IL223488A (pl)
LT (1) LT2579874T (pl)
MX (1) MX339209B (pl)
MY (1) MY171625A (pl)
NO (1) NO2579874T3 (pl)
NZ (1) NZ604026A (pl)
PL (1) PL2579874T3 (pl)
PT (1) PT2579874T (pl)
RS (1) RS56820B1 (pl)
RU (1) RU2607498C2 (pl)
SG (1) SG186200A1 (pl)
SI (1) SI2579874T1 (pl)
WO (1) WO2011154724A2 (pl)
ZA (1) ZA201209233B (pl)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8470359B2 (en) 2000-11-13 2013-06-25 Qlt Usa, Inc. Sustained release polymer
US9272044B2 (en) 2010-06-08 2016-03-01 Indivior Uk Limited Injectable flowable composition buprenorphine
GB2513060B (en) 2010-06-08 2015-01-07 Rb Pharmaceuticals Ltd Microparticle buprenorphine suspension
GB2481018B (en) 2010-06-08 2015-03-18 Rb Pharmaceuticals Ltd Injectable flowable composition comprising buprenorphine
WO2013126552A1 (en) * 2012-02-21 2013-08-29 Auburn University Buprenorphine nanoparticle composition and methods thereof
CA3120681C (en) 2012-04-17 2024-05-28 Purdue Pharma L.P. Systems and methods for treating an opioid-induced adverse pharmacodynamic response
AU2013294915C1 (en) 2012-07-26 2019-11-21 Camurus Ab Opioid formulations
CN109010255B (zh) * 2012-07-26 2022-10-21 卡姆拉斯公司 阿片样物质制剂
US20150320866A1 (en) * 2012-12-13 2015-11-12 Heron Therapeutics, Inc. Pharmaceutical composition comprising antiemetic compounds and polyorthoester
US9636308B2 (en) 2013-03-15 2017-05-02 Oakwood Laboratories LLC High drug load buprenorphine microspheres and method of producing same
US9393211B2 (en) 2013-03-15 2016-07-19 Oakwood Laboratories LLC High drug load buprenorphine microspheres and method of producing same
US9744163B2 (en) * 2013-03-15 2017-08-29 Heron Therapeutics, Inc. Compositions of a polyorthoester and an aprotic solvent
GB201404139D0 (en) * 2014-03-10 2014-04-23 Rb Pharmaceuticals Ltd Sustained release buprenorphine solution formulations
SI3134070T1 (sl) * 2014-04-21 2021-03-31 Heron Therapeutics, Inc. Sestave poliortoestra in pomožne snovi iz organske kisline
US9801945B2 (en) 2014-04-21 2017-10-31 Heron Therapeutics, Inc. Long-acting polymeric delivery systems
EP3936115A1 (en) 2014-04-21 2022-01-12 Heron Therapeutics, Inc. Long-acting polymeric delivery systems
WO2018048460A1 (en) 2014-04-21 2018-03-15 Heron Therapeutics, Inc. A pharmaceutical composition comprising a delivery system, an amide-type local anesthetic, and meloxicam
ES2658766T3 (es) 2014-04-28 2018-03-12 Orphomed, Inc. Dímero de buprenorfina y uso en el tratamiento de trastornos gastrointestinales
GB201419091D0 (en) * 2014-10-27 2014-12-10 Camurus Ab Formulations
CA2965895C (en) * 2014-11-07 2019-08-06 Indivior Uk Limited The use of sustained-release buprenorphine formulations for the treatment of pain or opioid use disorders
JP6949820B2 (ja) * 2015-08-03 2021-10-13 トルマー インターナショナル リミテッド 薬物の持続投与のための液体ポリマー送達システム
WO2017085561A1 (en) 2015-11-16 2017-05-26 Medincell A method for morselizing and/or targeting pharmaceutically active principles to synovial tissue
LT3512518T (lt) * 2016-09-13 2023-02-10 Alar Pharmaceuticals Inc. Sulėtinto atpalaidavimo buprenorfino vaisto formos
NZ760033A (en) 2017-06-16 2023-02-24 Indivior Uk Ltd Methods to treat opioid use disorder
US10646484B2 (en) 2017-06-16 2020-05-12 Indivior Uk Limited Methods to treat opioid use disorder
WO2019144079A1 (en) 2018-01-22 2019-07-25 Yuhua Li Pharmaceutical composition for sustained release delivery of buprenorphine
CN111954672B (zh) * 2018-05-11 2023-09-01 昱展新药生技股份有限公司 丁丙诺啡衍生物的长效注射制剂及结晶形式
EP3863712A4 (en) 2018-10-11 2022-07-20 Indivior UK Limited BUPRENORPHINE FOR TREATING RESPIRATORY DEPRESSION
US20210060316A1 (en) * 2019-08-30 2021-03-04 Intersect Ent, Inc. Submucosal bioresorbable drug eluting platform

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5702716A (en) 1988-10-03 1997-12-30 Atrix Laboratories, Inc. Polymeric compositions useful as controlled release implants
US4938763B1 (en) 1988-10-03 1995-07-04 Atrix Lab Inc Biodegradable in-situ forming implants and method of producing the same
US5324519A (en) 1989-07-24 1994-06-28 Atrix Laboratories, Inc. Biodegradable polymer composition
ES2171186T3 (es) 1994-04-08 2002-09-01 Atrix Lab Inc Composiciones liquidas de difusion.
US20030211157A1 (en) * 1996-05-06 2003-11-13 Simon David Lew Semi-sol delivery blend for water soluble molecules
US6565874B1 (en) 1998-10-28 2003-05-20 Atrix Laboratories Polymeric delivery formulations of leuprolide with improved efficacy
US6143314A (en) * 1998-10-28 2000-11-07 Atrix Laboratories, Inc. Controlled release liquid delivery compositions with low initial drug burst
US6461631B1 (en) 1999-11-16 2002-10-08 Atrix Laboratories, Inc. Biodegradable polymer composition
EP1509182A4 (en) * 2002-05-31 2009-12-30 Titan Pharmaceuticals Inc IMPLANTABLE POLYMERS DEVICE FOR THE DELAYED RELEASE OF BUPRENORPHINE
AU2003295409B2 (en) * 2002-11-06 2010-02-11 Durect Corporation Controlled release depot formulations
AU2004219595A1 (en) * 2003-03-11 2004-09-23 Qlt Usa Inc. Formulations for cell- schedule dependent anticancer agents
AU2005294382A1 (en) * 2004-10-04 2006-04-20 Qlt Usa, Inc. Ocular delivery of polymeric delivery formulations
JP5244394B2 (ja) * 2004-11-10 2013-07-24 トルマー セラピューティクス， インコーポレイテッド． 安定化されたポリマー送達系
ES2755374T3 (es) 2007-02-15 2020-04-22 Tolmar Therapeutics Inc Poli(lactida/glicolida) de descarga lenta y métodos para producir polímeros
US20090181068A1 (en) * 2008-01-14 2009-07-16 Dunn Richard L Low Viscosity Liquid Polymeric Delivery System
GB2481018B (en) 2010-06-08 2015-03-18 Rb Pharmaceuticals Ltd Injectable flowable composition comprising buprenorphine

Also Published As

Publication number Publication date
JP2013533230A (ja) 2013-08-22
JP2016155865A (ja) 2016-09-01
CN103079544A (zh) 2013-05-01
NZ604026A (en) 2015-01-30
IL254417A0 (en) 2017-11-30
CY1120761T1 (el) 2019-12-11
WO2011154724A3 (en) 2012-07-12
WO2011154724A9 (en) 2012-08-16
RS56820B1 (sr) 2018-04-30
RU2012157244A (ru) 2014-07-20
ZA201209233B (en) 2014-04-30
KR20130135026A (ko) 2013-12-10
GB201413064D0 (en) 2014-09-03
AU2011263478A1 (en) 2013-01-10
CO6670529A2 (es) 2013-05-15
WO2011154724A2 (en) 2011-12-15
SG186200A1 (en) 2013-01-30
MX2012014335A (es) 2013-03-05
CL2012003462A1 (es) 2013-04-01
EP2579874A2 (en) 2013-04-17
EP4218720A1 (en) 2023-08-02
ES2939612T3 (es) 2023-04-25
CA2801676C (en) 2018-08-07
CA2801676A1 (en) 2011-12-15
GB2513267B (en) 2015-03-18
BR112012031290A2 (pt) 2016-11-01
DK2579874T3 (da) 2018-01-29
CN103079544B (zh) 2017-06-09
LT2579874T (lt) 2018-02-12
IL223488A (en) 2017-10-31
MX339209B (es) 2016-04-15
HRP20180118T1 (hr) 2018-03-09
NO2579874T3 (pl) 2018-06-09
US8921387B2 (en) 2014-12-30
FI3360538T3 (fi) 2023-03-22
HUE038275T2 (hu) 2018-10-29
GB2481018A (en) 2011-12-14
RU2607498C2 (ru) 2017-01-10
SI2579874T1 (en) 2018-03-30
DK3360538T3 (da) 2023-03-06
ES2656938T3 (es) 2018-03-01
EP3360538B1 (en) 2023-02-15
MY171625A (en) 2019-10-21
KR101865689B1 (ko) 2018-06-08
GB2513267A (en) 2014-10-22
GB201009549D0 (en) 2010-07-21
JP5986072B2 (ja) 2016-09-06
EP3360538A1 (en) 2018-08-15
GB2481018B (en) 2015-03-18
US20130210853A1 (en) 2013-08-15
PT2579874T (pt) 2018-01-29
EP2579874B1 (en) 2018-01-10
JP6251774B2 (ja) 2017-12-20
AU2011263478B2 (en) 2015-01-22

Similar Documents

Publication Publication Date Title
IL254417A0 (en) A flowable, injectable preparation containing buprenorphine
GB201002983D0 (en) Nutritinal composition
GB201006200D0 (en) Composition
GB201021186D0 (en) Composition
RS55517B1 (sr) Supstance koje sadrže buprenorfin
HK1174802A1 (en) Composite additive materials
GB201006178D0 (en) Composition
HK1163562A1 (en) Dermal filler composition
GB201017048D0 (en) Composition
IL206739A0 (en) Injectable pharmaceutical composition
GB201019988D0 (en) Composition
GB201016970D0 (en) Composition
GB201007531D0 (en) Composition
GB201006214D0 (en) Composition
GB201006204D0 (en) Composition
GB201004717D0 (en) Composition
GB201014967D0 (en) Composition
GB201010657D0 (en) Composition
GB201006175D0 (en) Composition
GB201018130D0 (en) Composition
GB201006182D0 (en) Composition
GB201006012D0 (en) Composition
GB201002356D0 (en) Composition
GB201017987D0 (en) Composition
GB201012820D0 (en) Composition